8-K: Hims & Hers Health Inc. Reports Strong 2023 Results, Achieves Profitability and Provides Optimistic 2024 Guidance

Hims & Hers Health, Inc. announced a 65% year-over-year revenue increase for 2023, achieving net income profitability in Q4 and providing strong guidance for 2024.

Summary

• Hims & Hers Health, Inc. reported a significant 65% year-over-year revenue increase for 2023, reaching $872 million.
• The company achieved net income of $1.2 million in the fourth quarter of 2023, a substantial improvement from a net loss of $10.9 million in the same quarter of the previous year.
• Adjusted EBITDA for Q4 2023 was $20.6 million, compared to $3.9 million in Q4 2022.
• The company's subscriber base grew to 1.5 million by the end of 2023, a 48% increase year-over-year.
• Hims & Hers provided a full year 2024 revenue guidance of $1.17 billion to $1.20 billion and an adjusted EBITDA guidance of $100 million to $120 million.
• The company expects to achieve its 2025 Adjusted EBITDA target one year early and has a direct line of sight to its 2025 revenue target.
• Gross margin for the full year 2023 was 82%, up from 78% in 2022.
• Net loss for the full year 2023 was $(23.5) million, a significant improvement from $(65.7) million in 2022.
• Free cash flow for the full year 2023 was $47.0 million, compared to $(33.8) million in 2022.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to strong revenue growth, achievement of profitability, and optimistic future guidance. The company's performance significantly exceeded expectations, indicating a strong and healthy business.

Positives

• The company demonstrated strong revenue growth, with a 65% increase year-over-year in 2023.
• Hims & Hers achieved profitability in Q4 2023 with a net income of $1.2 million.
• The subscriber base grew significantly, indicating strong customer adoption and retention.
• Adjusted EBITDA showed substantial improvement, demonstrating operational efficiency.
• The company provided optimistic guidance for 2024, projecting continued revenue growth and profitability.
• Gross margin improved year-over-year, indicating better cost management.
• Free cash flow turned positive for the full year 2023, showcasing improved financial health.

Negatives

• The company reported a net loss of $(23.5) million for the full year 2023, although this is a significant improvement from the previous year.
• Monthly online revenue per average subscriber decreased slightly in Q4 2023, from $55 to $53.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• The company's ability to achieve its financial targets depends on various factors, including market conditions and regulatory changes.
• The company's reliance on online sales and subscriptions makes it vulnerable to changes in consumer behavior and preferences.
• The company faces competition from other healthcare providers and platforms.

Future Outlook

Hims & Hers expects full year 2024 revenue to be in the range of $1.17 billion to $1.20 billion and Adjusted EBITDA to be in the range of $100 million to $120 million. The company anticipates achieving its 2025 Adjusted EBITDA target one year early and has a direct line of sight to its 2025 revenue target.

Management Comments

• Andrew Dudum, co-founder and CEO, stated that the outstanding results in 2023 underscore the power of the Hims & Hers brands and superior execution across the organization.
• Andrew Dudum mentioned that the company is continuing to advance its mission to make the world feel great through the power of better health.
• Yemi Okupe, CFO, stated that the strong momentum is the direct result of a simple but powerful strategy to provide users with access to high quality personalized care that is attractively priced and backed by a delightful experience.

Industry Context

The results reflect the growing trend of telehealth and digital health platforms, with Hims & Hers demonstrating strong growth and profitability in this sector. The company's focus on personalized care and subscription-based services aligns with the increasing demand for convenient and accessible healthcare solutions.

Comparison to Industry Standards

• Hims & Hers' 65% revenue growth significantly outpaces the average growth rate of many traditional healthcare providers and is competitive with other high-growth telehealth companies.
• The company's achievement of profitability in Q4 2023 is a notable milestone, as many telehealth companies are still focused on growth over profitability.
• The subscriber growth of 48% year-over-year demonstrates strong market acceptance and customer loyalty, which is a key metric for subscription-based businesses.
• The projected 2024 revenue of $1.17 billion to $1.20 billion positions Hims & Hers as a significant player in the digital health market, comparable to other established telehealth platforms such as Teladoc and Amwell, although they operate in slightly different market segments.
• The adjusted EBITDA margin of 8-10% for Q1 2024 and 9-10% for full year 2024 is a positive sign of operational efficiency and is in line with or better than some of its peers in the digital health space.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and optimistic guidance.
• Employees may be motivated by the company's success and growth prospects.
• Customers will benefit from the company's continued focus on personalized and accessible healthcare.
• Suppliers and creditors may view the company as a more stable and reliable partner due to its improved financial health.

Next Steps

• The company will host a conference call on February 26, 2024, to review the fourth quarter and full year 2023 results.
• The company will continue to focus on building personalized and accessible treatments in its core specialties.
• The company will continue to execute its strategy to provide users with access to high quality personalized care.

Key Dates

Keywords

Hims & Hers, telehealth, digital health, subscription, revenue, EBITDA, profitability, financial results, healthcare, wellness